Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

4.200 +0.140 (+3.45%)

Streaming Delayed Price Updated: 10:37 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Earnings Outlook For Aldeyra Therapeutics ↗

March 08, 2023

Via Benzinga

FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma

March 02, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights

March 01, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients ↗

February 28, 2023

Via Benzinga

Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder ↗

October 06, 2022

Via Benzinga

Recap: Aldeyra Therapeutics Q2 Earnings ↗

August 05, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease

February 28, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy

February 23, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials

February 16, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

February 09, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

February 07, 2023

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma

December 21, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication ↗

December 13, 2022

Via Benzinga

Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

December 13, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

December 01, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

November 29, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights

November 10, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

November 03, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting

October 26, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

October 06, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

October 05, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary ↗

September 14, 2022

Via Benzinga

Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones

September 14, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

September 07, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying ↗

August 08, 2022

Although US stocks closed mixed on Friday, there were a few notable insider trades.

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights

August 05, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Earnings Outlook For Aldeyra Therapeutics ↗

August 04, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra...

Via Benzinga

Earnings Scheduled For August 5, 2022 ↗

August 05, 2022

Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.